Dioseve utilizes Directly Induced Oocyte-like cells (DIOLs) technology to rapidly generate egg-like cells from induced pluripotent stem cells, enabling significant advancements in reproductive health. This approach provides solutions for infertility treatments and the investigation of genetic disorders, addressing critical gaps in current biomedical capabilities.
Funding
$16.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
SCFounders
Product
Problem
Infertility rates are rising due to factors such as aging, declining sperm quality, and various reproductive disorders, leaving many individuals and couples unable to conceive naturally. Current assisted reproductive technologies (ART) have limitations in terms of egg availability, success rates, and accessibility.
Solution
Dioseve is developing a novel platform for generating human oocyte-like cells (DIOLs) from induced pluripotent stem cells (iPSCs). Their proprietary differentiation induction technology enables the efficient and scalable production of DIOLs and ovarian somatic cells. This approach bypasses the need for primordial germ cells, directly differentiating iPSCs into oogonia, the precursor to oocytes. Dioseve's technology aims to provide a readily available source of egg cells for fertility treatments, overcoming limitations associated with traditional methods and offering new possibilities for individuals facing infertility challenges.
Target Audience
The primary target audience includes individuals and couples struggling with infertility, fertility clinics, and research institutions investigating reproductive biology and genetic disorders.
Features
- Directly Induced Oocyte-like cells (DIOLs) technology for rapid generation of egg-like cells
- High-efficiency differentiation of iPS cells into oocytes and ovarian somatic cells
- Scalable production process for generating large quantities of DIOLs
- Potential to create egg cells from male-derived iPSCs
- Streamlined differentiation process, reducing the time required for oocyte generation compared to existing methods
- DIOS-001 pipeline focusing on infertility treatment
- DIOS-101 pipeline focusing on investigating the causes of genetic disorders